

Number (Optional) **5790-01-CA**

Applicant(s)
BISGAIER, CHARLES LARRY

Group Art Unit

[illegible]

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
9	93/13801	07/22/1993	WO	—	—	✓	
	0 738 510 A2	10/23/1996	EP	J	I		✓
	97/14403	04/24/1997	WO	J	I	✓	
2	93/16690	09/02/1993	WO	—	—	✓	

		Glueck, et al, The American Journal of Card., "Gemfibrozil-Lovastatin Therapy for Primary Hyperlipoproteinemias" 1992, Vol. 70:1 PP. 1-9.
22		Haag, et al., Cellular Singalling, "Lovastatin Inhibits Receptors-Stimulated Ca2+-Influx in Retinoic Acid Differentiated U937 and HL-60 Cells" 1994, Vol. 6:7; PP. 735-742
23		Ramires, et al., Intern'l Journal of Card., "Effect of Gemfibrozil Versus Lovastatin on Increased Serum Lipoprotein(a) levels of patients with hypercholesterolemia", 1995, vol. 48:2; PP. 115-120.
24		Dimitroulakis, et al., Nature Medicine, "HMG-CoA Reductase Mediates the Biological Effects of Retinoic Acid On Human Neuroblastoma Cells: Lovastatin Specifically Targets P-Glycoprotein-Expressing Cells" 1996, 2:3 PP. 326-333

DATE CONSIDERED

Form PTO-A820
(also form PTO-1449)

P09A/REV04

Patent and Trademark Office • U.S. DEPARTMENT OF COMMERCE

SHEET

OF

Docket No.: 5790-C1-HMB

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

5790-01-CA

Application Number

09/485242

Applicant(s)

BISGAIER, CHARLES LARRY

Filing Date

FEBRUARY 7, 2000

Group Art Unit

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

8	Ramharack, et al., Biochemical and Biophysical Research Comm., "Retinoids Inhibit Primary cynomolgus Monkey Hepatocyte Lipoprotein(a) Levels" 1997, Vol. 238:1, PP. 48-52
9	Krause, et al., Expert Opinion on Investigational Drugs, "Emerging Therapies in Atherosclerosis", 1995, Vol. 4:5, PP. 353-387
10	PCT International Search Report, PCT/US98/23480

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

+

+

2

5790-C1

[illegible][illegible]

6/04

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

+

+

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/647,358
Filing Date	August 5, 2003
First Named Inventor	Charles L. Bisgaier
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	5790-C1

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**